Evidence map›Paper›PMID 41334173›Full record

ArticleJugan geon-gang gwa jilbyeong2023

Se-Jin Jeong, Misuk An, Minjeong Jang, So Young Choi, You-Jung Choi, Jinhwa Jang, Boyeong Ryu, Shin Young Park, Seong-Sun Kim

Abstract readCase ReportsEnglish Abstract
In one paragraph

Article in Jugan geon-gang gwa jilbyeong, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. COVID-19 Vaccination Strategy and Evidence in Korea.Journal of Korean medical science · 2026
    Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Se-Jin Jeong질병관리청 중앙방역대책본부 역학조사분석단 정보분석팀.
Misuk An질병관리청 중앙방역대책본부 역학조사분석단 정보분석팀.
Minjeong Jang질병관리청 중앙방역대책본부 역학조사분석단 정보분석팀.
So Young Choi질병관리청 중앙방역대책본부 역학조사분석단 정보분석팀.
You-Jung Choi질병관리청 중앙방역대책본부 역학조사분석단 정보분석팀.
Jinhwa Jang질병관리청 중앙방역대책본부 역학조사분석단 정보분석팀.
Boyeong Ryu질병관리청 중앙방역대책본부 역학조사분석단 정보분석팀.
Shin Young Park질병관리청 중앙방역대책본부 역학조사분석단 정보분석팀.
Seong-Sun Kim질병관리청 중앙방역대책본부 역학조사분석단 정보분석팀.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report seeks to compare and analyze the severity trends of coronavirus disease 2019 (COVID-19) in Republic of Korea during periods of dominant variant virus prevalence. The analysis covers the period from January 20, 2020, to July 31, 2023, categorizing the severity of COVID-19 cases both throughout the entire period and during periods of dominant variant virus prevalence. Up until July 31, 2023, a total of 34,082,179 confirmed cases of COVID-19 have been recorded, resulting in 37,760 cases (0.11%) of severe illness and 35,644 deaths (0.11%). During the dominant prevalence of the Omicron BA.1 and BA.2 variants (from January 16, 2022 to July 9, 2022), severe cases and deaths were most widespread, accounting for 10,460 cases (27.7%) of severe illness and 18,679 deaths (52.4%). Concerning case severity rate and case fatality rate, the period before the dominant prevalence of the Delta variant (from January 20, 2020 to July 24, 2021) had the highest rates at 2.98% and 1.15%, respectively. In contrast, during the dominant prevalence of the Omicron XBB variant (from April 16, 2023 to July 31, 2023), these rates were at their lowest, reaching 0.12% for severity and 0.04% for fatality. Despite the continuous emergence of new variant viruses after the onset of COVID-19, the case severity rate during the dominant prevalence of the Omicron XBB variant has decreased to 0.04%, comparable to the risk level seen with influenza. However, the case fatality rate by age group is <0.01% for 0-49 years old, 0.01% for 50-59 years old, and 0.03% for 60-69 years old, while the case fatality rate for 80+ years old is 0.56%, which is still higher than other age groups, so the prevention policy of prioritizing high-risk groups should be continued.

Indexed as

COVID-19COVID-19 deathsCOVID-19 severityCOVID-19 variantsSARS-CoV-2

Identifiers

PMID41334173
PMCPMC12479829

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.